Opioid Dependency After Craniomaxillofacial Trauma Surgery

颅颌面创伤手术后阿片类药物依赖

阅读:1

Abstract

OBJECTIVE: The opioid crisis has led to significant morbidity and mortality. A component of this is attributable to overdoses on prescribed opioids. A prior study estimated that 39% of opioid prescriptions after craniomaxillofacial (CMF) trauma were potentially inappropriate prescriptions. The goal of this study was to identify factors associated with potentially inappropriate and prolonged opioid prescriptions in the postoperative CMF trauma patient population. STUDY DESIGN: Retrospective cohort. SETTING: Merative™ MarketScan® Commercial & Multi-State Medicaid Databases (2015-2022). METHODS: Patients undergoing CMF trauma surgery were identified and stratified based on whether they had commercial versus Medicaid insurance. The association of prolonged opioid prescription length with demographic, comorbid, and surgical factors was investigated. RESULTS: A total of 23,985 patients from 2015 to 2022 underwent CMF trauma surgery and received postoperative opioid prescriptions. The average prescription length was significantly lower in the commercially insured cohort versus the Medicaid cohort (24.6 days vs 33.7 days), and 22% of prescriptions were potentially inappropriate in nature. A diagnosis of chronic pain, as well as having 2 overlapping opioid prescriptions or an extended-release opioid prescription, had the highest adjusted odds of a prescription longer than 30 days. CONCLUSION: Although potentially inappropriate prescriptions after CMF trauma surgery decreased from a prior estimate (39% vs 22%), inappropriate prescribing practices are highly associated with prolonged opioid prescriptions. Providers must ensure patients do not have an existing opioid prescription before writing an additional one and should not dispense extended-release formulations in the acute postoperative setting.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。